MedTrace Logo

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

NCT02575833 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2018-08-24

Study results available
· View outcomes & findings →

Summary

A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.

Conditions

  • Stable Angina

Interventions

DRUG

Erenumab

A single dose of erenumab 140 mg infused over approximately 60 minutes.

DRUG

Placebo

A single dose of a matching volume of placebo infused over approximately 60 minutes.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2017-01-23
Completion
2017-04-13

Countries

  • United States
  • Bulgaria
  • Czechia
  • Latvia
  • New Zealand
  • Poland
  • Romania
  • Slovakia
  • South Africa
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02575833 on ClinicalTrials.gov